Operations and Business Environment - Fresenius Medical Care

In terms of dialysis products, we were able to raise our
revenue by 11% to $ 2.12 billion. Currency-adjusted,
the increase was 11%. Including revenue with our own
dialysis clinics, the revenue with dialysis products rose
by 13 % to $ 2.77 billion. The increase in constant currency
was 12 %. Dialysis products accounted for 25 %
of Fresenius Medical Care’s overall revenue, following
a contribution of 28 % in 2005.
Both segments – North America and International –
contributed to the revenue growth. Growth in North
American revenue was above average – due to the
acquisition of the Renal Care Group – expanding by
32 % to about $ 6.03 billion (2005: $ 4.58 billion).
International revenue rose by 13 % reaching about
$ 2.47 billion. Currency-adjusted growth in the International
region was 12 %.
North America was and is by far the most important
market for Fresenius Medical Care. In 2006, we achieved
about 71% of our total revenue there, compared to
68 % in 2005. The share increased due to RCG’s revenue
contribution.
Patients
2006 2005 Change
North America
Europe / Middle East / Africa
Latin America
Asia-Pacific
Total
117,855
25,078
16,924
3,660
163,517
89,300
22,850
15,800
3,500
131,450
32 %
10 %
7 %
4 %
24 %
69
Treatments
in millions 2006 2005 Change
North America
Europe / Middle East / Africa
Latin America
Asia-Pacific
Total
16.88
3.76
2.55
0.55
23.74
13.47
3.38
2.37
0.51
19.73
25 %
11%
7 %
8 %
20 %
Clinics
2006 2005 Change
North America
Europe / Middle East / Africa
Latin America
Asia-Pacific
Total
1,560
342
166
40
2,108
1,157
323
159
41
1,680
35 %
6 %
4 %
- 2 %
25 %
Fresenius Medical Care 2006